Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544301 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2024014308 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
J Immunother Cancer
November 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
B-cell maturation antigen(BCMA)-directed chimeric antigen receptor (CAR)-T-cell therapy has significantly improved the treatment of relapsed or refractory multiple myeloma (MM). Nevertheless, the uncommon phenomenon of biphasic CAR-T cell expansion in vivo and its related severe toxicities have not been methodically described and studied. Herein, we report a case of patients with MM who experienced two CAR-T cell expansion peaks and subsequently developed multiple severe toxicities following BCMA CAR-T cell infusion.
View Article and Find Full Text PDFCytopenias in BCMA CAR T: unraveling inflammatory mechanisms.
Blood Adv
November 2024
Division of Hematology, Brigham and Women's Hospital, Boston, MA.
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice.
Ann Pharmacother
October 2024
Division of Pharmacy, Atrium Health Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Article Synopsis
- - The objective of the review was to examine the pharmacology, safety, and effectiveness of BCMA-directed immunotherapies, such as CAR-T therapy and bispecific antibodies, for treating relapsed/refractory multiple myeloma (RRMM).
- - Evidence from phase III and II clinical trials shows that BCMA-directed therapies like idecabtagene vicleucel and teclistamab significantly improve response rates and progression-free survival compared to standard treatments for RRMM.
- - Despite their benefits, these therapies pose safety risks (like cytokine release syndrome) and face challenges in patient access due to the need for specialized administration and monitoring facilities.
Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma.
Cytotherapy
January 2025
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address:
Background: Many studies have demonstrated the effectiveness of chimeric antigen receptor-T (CAR-T) cell therapy for relapsed or refractory multiple myeloma (RRMM), but the hematologic toxicity has not been well characterized.
Methods: A total of 111 adults with RRMM who received BCMA CAR-T cells, BCMA + CD19 CAR-T cells or tandem BCMA/CD19 dual-target (BC19) CAR-T cells infusion were enrolled. We characterized cytopenia and hematologic recovery at different time points after CAR-T-cell therapy, analyzed the effect of cytopenia on prognosis and identified the risk factors.
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Blood
December 2024
Division of Hematology Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Article Synopsis
- Teclistamab is a bispecific antibody approved for treating patients with relapsed/refractory multiple myeloma who have previously undergone multiple treatments, including BCMA-targeted therapies.
- In a clinical study (MajesTEC-1), patients with a median of six prior treatments received weekly doses of teclistamab, resulting in a 52.5% overall response rate with some achieving complete remission.
- The treatment had manageable side effects, with common adverse events including neutropenia and infections, while showing a median overall survival of 15.5 months in heavily pretreated patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!